Immunotherapy of cancers with checkpoint inhibitor blocking antibodies, such as anti-PD-L1 or anti-CTLA4, is only effective for about 1⁄4 of patients with preexisting tumor-infiltrating effector T cells [12, 13]. The gene discussed is CTLA4; the disease is neoplasm.